Result:Weak· Market: Crashed#Base effect
| Metric | Value (₹ Cr) | Q1 FY26 |
|---|---|---|
| Revenue | 2.41 | 17.4% |
| Total Income | 2.51 | 14.4% |
| Expenditure | 4.70 | 26.1% |
| PBT | -2.19 | 36.1% |
| Net Profit | -2.19 | 36.2% |
| OPM | -89.22% | |
| NPM | -87.02% | |
| EPS | 2.16 | 36.3% |
Pharma core metric (revenue) declined 17.4% YoY and the company remains in a loss despite a smaller absolute loss, so the narrower deficit is a base effect on a tiny depressed base rather than genuine improvement.
Informational and educational content only. Not investment advice.